{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:38:18Z","timestamp":1787981898939,"version":"build-2784847793"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recently, <jats:italic>Mycobacterium avium<\/jats:italic> complex (MAC) infections have been increasing, especially in immunocompromised and older adults. The rapid increase has triggered a global health concern due to limited therapeutic strategies and adverse effects caused by long-term medication. To provide more evidence for the treatment of MAC, we studied the in vitro inhibitory activities of 17 antimicrobial agents against clinical MAC isolates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 111 clinical MAC isolates were enrolled in the study and they were identified as <jats:italic>M. intracellulare<\/jats:italic>, <jats:italic>M. avium<\/jats:italic>, <jats:italic>M. marseillense<\/jats:italic>, <jats:italic>M. colombiense<\/jats:italic>, <jats:italic>M. yongonense<\/jats:italic>, and two isolates could not be identified at the species level. MAC strains had relatively low (0\u201321.6%) resistance to clarithromycin, amikacin, bedaquiline, rifabutin, streptomycin, and clofazimine, and the resistant rates to isoniazid, rifampin, linezolid, doxycycline, and ethionamide were very high (72.1\u2013100%). In addition, <jats:italic>M. avium<\/jats:italic> had a significantly higher resistance rate than that of <jats:italic>M. intracellulare<\/jats:italic> for ethambutol (92.3% vs 40.7%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), amikacin (15.4% vs 1.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.049), and cycloserine (69.2% vs 25.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.004).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results supported the current usage of macrolides, rifabutin, and aminoglycosides in the regimens for MAC infection, and also demonstrated the low resistance rate against new drugs, such as clofazimine, tedizolid, and bedaquiline, suggesting the possible implementation of these drugs in MAC treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-022-02582-2","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:02:38Z","timestamp":1657256558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates"],"prefix":"10.1186","volume":"22","author":[{"given":"Siran","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"8","key":"2582_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S1473-3099(15)00089-4","volume":"15","author":"UI Wu","year":"2015","unstructured":"Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15(8):968\u201380.","journal-title":"Lancet Infect Dis"},{"key":"2582_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-016-0606-6","volume":"14","author":"MA Lake","year":"2016","unstructured":"Lake MA, Ambrose LR, Lipman MC, Lowe DM. \u2019 \u201cWhy me, why now?\u201d using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. Bmc Med. 2016;14:54.","journal-title":"Bmc Med"},{"issue":"6","key":"2582_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3201\/eid2206.151860","volume":"22","author":"F Valour","year":"2016","unstructured":"Valour F, Perpoint T, S\u00e9n\u00e9chal A, Kong XF, Bustamante J, Ferry T, Chidiac C, Ader F. Interferon-\u03b3 autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22(6):1124\u20136.","journal-title":"Emerg Infect Dis"},{"key":"2582_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fpubh.2020.00295","volume":"8","author":"L Zhou","year":"2020","unstructured":"Zhou L, Xu D, Liu H, Wan K, Wang R, Yang Z. Trends in the prevalence and antibiotic resistance of non-tuberculous mycobacteria in Mainland China, 2000\u20132019: systematic review and meta-analysis. Front Public Health. 2020;8:295.","journal-title":"Front Public Health"},{"issue":"6","key":"2582_CR5","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.3390\/ijms22063011","volume":"22","author":"MK Shin","year":"2021","unstructured":"Shin MK, Shin SJ. Genetic involvement of mycobacterium avium complex in the regulation and manipulation of innate immune functions of host cells. Int J Mol Sci. 2021;22(6):3011.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2582_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jiac.2019.11.004","volume":"26","author":"N Riccardi","year":"2020","unstructured":"Riccardi N, Monticelli J, Antonello RM, Luzzati R, Gabrielli M, Ferrarese M, Codecasa L, Di Bella S, Giacobbe DR. Mycobacterium chimaera infections: An update. J Infect Chemother. 2020;26(3):199\u2013205.","journal-title":"J Infect Chemother"},{"key":"2582_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IDR.S282190","volume":"14","author":"X Yu","year":"2021","unstructured":"Yu X, Jiang W. Mycobacterium colombiense and Mycobacterium avium complex causing severe Pneumonia in a patient with HIV identified by a novel molecular-based method. Infect Drug Resist. 2021;14:11\u20136.","journal-title":"Infect Drug Resist"},{"issue":"10","key":"2582_CR8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3201\/eid2510.190695","volume":"25","author":"B Xie","year":"2019","unstructured":"Xie B, Chen Y, Wang J, Gao W, Jiang H, Sun J, Jin X, Sang X, Yu X, Wang H. Mycobacterium marseillense infection in human skin, China, 2018. Emerg Infect Dis. 2019;25(10):1991\u20133.","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"2582_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1017\/ice.2020.1226","volume":"42","author":"J Kimsis","year":"2021","unstructured":"Kimsis J, Pole I, Norvaisa I, Dumpis U, Ranka R. Characterization of Mycobacterium chimaera in a heater-cooler unit in Latvia. Infect Control Hosp Epidemiol. 2021;42(9):1168\u201370.","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"3","key":"2582_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3201\/eid2603.180452","volume":"26","author":"TL Lamagni","year":"2020","unstructured":"Lamagni TL, Charlett A, Phin N, Zambon M, Chand M. Invasive Mycobacterium chimaera infections and heater-cooler devices in cardiac surgery. Emerg Infect Dis. 2020;26(3):632.","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"2582_CR11","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1128\/JB.05928-11","volume":"193","author":"M Gonz\u00e1lez-P\u00e9rez","year":"2011","unstructured":"Gonz\u00e1lez-P\u00e9rez M, Murcia MI, Landsman D, Jordan IK, Mari\u00f1o-Ram\u00edrez L. Genome sequence of the Mycobacterium colombiense type strain, CECT 3035. J BACTERIOL. 2011;193(20):5866\u20137.","journal-title":"J BACTERIOL"},{"issue":"Pt 11","key":"2582_CR12","first-page":"2803","volume":"59","author":"SI Ben","year":"2009","unstructured":"Ben SI, Cayrou C, Raoult D, Drancourt M. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov., and Mycobacterium bouchedurhonense sp. nov., members of the Mycobacterium avium complex. Int J Syst Evol Microbiol. 2009;59(Pt 11):2803\u20138.","journal-title":"Int J Syst Evol Microbiol."},{"issue":"Pt 9","key":"2582_CR13","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1099\/ijs.0.64190-0","volume":"56","author":"MI Murcia","year":"2006","unstructured":"Murcia MI, Tortoli E, Menendez MC, Palenque E, Garcia MJ. Mycobacterium colombiense sp. nov., a novel member of the Mycobacterium avium complex and description of MAC-X as a new ITS genetic variant. Int J Syst Evol Microbiol. 2006;56(Pt 9):2049\u201354.","journal-title":"Int J Syst Evol Microbiol."},{"key":"2582_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2334-13-24","volume":"13","author":"S Poulin","year":"2013","unstructured":"Poulin S, Corbeil C, Nguyen M, St-Denis A, C\u00f4t\u00e9 L, Le Deist F, Carignan A. Fatal Mycobacterium colombiense\/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. Bmc Infect Dis. 2013;13:24.","journal-title":"Bmc Infect Dis"},{"issue":"6","key":"2582_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2340\/00015555-1828","volume":"94","author":"W Gao","year":"2014","unstructured":"Gao W, Chen H, Jiang H, Wang Q, Tang M, Wang HS. Disseminated cutaneous infection caused by Mycobacterium colombiense. Acta Derm Venereol. 2014;94(6):727\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2582_CR16","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1128\/JCM.01441-07","volume":"46","author":"O Esparcia","year":"2008","unstructured":"Esparcia O, Navarro F, Quer M, Coll P. Lymphadenopathy caused by Mycobacterium colombiense. J Clin Microbiol. 2008;46(5):1885\u20137.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2582_CR17","doi-asserted-by":"publisher","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","volume":"50","author":"WJ Koh","year":"2017","unstructured":"Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50(3):1602503.","journal-title":"Eur Respir J."},{"issue":"2","key":"2582_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1378\/chest.13-2538","volume":"146","author":"RJ Wallace","year":"2014","unstructured":"Wallace RJ, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide\/Azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276\u201382.","journal-title":"Chest"},{"issue":"11","key":"2582_CR19","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1513\/AnnalsATS.201605-344BC","volume":"13","author":"DP Boyle","year":"2016","unstructured":"Boyle DP, Zembower TR, Qi C. Relapse versus reinfection of Mycobacterium avium complex pulmonary disease patient characteristics and macrolide susceptibility. Ann Am Thorac Soc. 2016;13(11):1956\u201361.","journal-title":"Ann Am Thorac Soc."},{"issue":"1","key":"2582_CR20","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, B\u00f6ttger EC, Brozek J, Griffith DE, Guglielmetti L, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535.","journal-title":"Eur Respir J."},{"issue":"8","key":"2582_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2582_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","volume":"195","author":"KN Olivier","year":"2017","unstructured":"Olivier KN, Griffith DE, Eagle G, McGinnis JN, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, et al. Randomized trial of Liposomal Amikacin for inhalation in nontuberculous Mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195(6):814\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2582_CR23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O\u2019Donnell AE, Marras TK, Flume PA, et al. Amikacin Liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559\u201369.","journal-title":"Am J Respir Crit Care Med."},{"key":"2582_CR24","doi-asserted-by":"publisher","first-page":"638306","DOI":"10.3389\/fmed.2021.638306","volume":"8","author":"MJ Nasiri","year":"2021","unstructured":"Nasiri MJ, Calcagno T, Hosseini SS, Hematian A, Nojookambari NY, Karimi-Yazdi M, Mirsaeidi M. Role of clofazimine in treatment of Mycobacterium avium complex. Front Med (Lausanne). 2021;8:638306.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"2582_CR25","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/jcm9092968","volume":"9","author":"BG Kim","year":"2020","unstructured":"Kim BG, Kim H, Kwon OJ, Huh HJ, Lee NY, Baek SY, Sohn I, Jhun BW. Outcomes of inhaled Amikacin and Clofazimine-containing regimens for treatment of refractory Mycobacterium avium complex pulmonary disease. J Clin Med. 2020;9(9):2968.","journal-title":"J Clin Med."},{"issue":"2","key":"2582_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","volume":"159","author":"N Kwak","year":"2021","unstructured":"Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal inhibitory concentration of Clofazimine among clinical isolates of nontuberculous Mycobacteria and its impact on treatment outcome. Chest. 2021;159(2):517\u201323.","journal-title":"Chest"},{"issue":"2","key":"2582_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.14-2764","volume":"148","author":"JV Philley","year":"2015","unstructured":"Philley JV, Wallace RJ, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous Mycobacterial lung disease. Chest. 2015;148(2):499\u2013506.","journal-title":"Chest"},{"issue":"suppl 2","key":"2582_CR28","doi-asserted-by":"publisher","first-page":"i30","DOI":"10.1093\/jac\/dkx305","volume":"72","author":"D Deshpande","year":"2017","unstructured":"Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. J Antimicrob Chemother. 2017;72(suppl 2):i30\u20135.","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"2582_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jmii.2017.05.001","volume":"51","author":"CC Huang","year":"2018","unstructured":"Huang CC, Wu MF, Chen HC, Huang WC. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. J Microbiol Immunol Infect. 2018;51(5):636\u201343.","journal-title":"J Microbiol Immunol Infect"},{"issue":"Pt 12","key":"2582_CR30","first-page":"3715","volume":"154","author":"SI Ben","year":"2008","unstructured":"Ben SI, Ad\u00e9kambi T, Raoult D, Drancourt M. rpoB sequence-based identification of Mycobacterium avium complex species. Microbiology (Reading). 2008;154(Pt 12):3715\u201323.","journal-title":"Microbiology (Reading)"},{"key":"2582_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fmicb.2020.00081","volume":"11","author":"J Jaffr\u00e9","year":"2020","unstructured":"Jaffr\u00e9 J, Aubry A, Maitre T, Morel F, Brossier F, Robert J, Sougakoff W, Veziris N. Rational choice of antibiotics and media for mycobacterium avium complex drug susceptibility testing. Front Microbiol. 2020;11:81.","journal-title":"Front Microbiol"},{"key":"2582_CR32","first-page":"4902941","volume":"2018","author":"Y Shen","year":"2018","unstructured":"Shen Y, Wang X, Jin J, Wu J, Zhang X, Chen J, Zhang W. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int. 2018;2018:4902941.","journal-title":"Biomed Res Int"},{"key":"2582_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijid.2020.02.059","volume":"93","author":"N Wetzstein","year":"2020","unstructured":"Wetzstein N, Kohl TA, Andres S, Schultze TG, Geil A, Kim E, Biciusca T, H\u00fcgel C, Hogardt M, Lehn A, et al. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex. Int J Infect Dis. 2020;93:320\u20138.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"2582_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cmi.2018.06.010","volume":"25","author":"FP Maurer","year":"2019","unstructured":"Maurer FP, Pohle P, Kernbach M, Sievert D, Hillemann D, Rupp J, Hombach M, Kranzer K. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex. Clin Microbiol Infect. 2019;25(3):371\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"2582_CR35","doi-asserted-by":"publisher","first-page":"e00491","DOI":"10.1128\/AAC.00491-18","volume":"62","author":"BS Kwon","year":"2018","unstructured":"Kwon BS, Kim MN, Sung H, Koh Y, Kim WS, Song JW, Oh YM, Lee SD, Lee SW, Lee JS, et al. In Vitro MIC values of Rifampin and Ethambutol and treatment outcome in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2018;62(10):e00491-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"2582_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJM199608083350602","volume":"335","author":"SD Shafran","year":"1996","unstructured":"Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV trials network protocol 010 study group. N Engl J Med. 1996;335(6):377\u201383.","journal-title":"N Engl J Med."},{"key":"2582_CR37","doi-asserted-by":"publisher","first-page":"645264","DOI":"10.3389\/fphar.2021.645264","volume":"12","author":"GD Boorgula","year":"2021","unstructured":"Boorgula GD, Jakkula L, Gumbo T, Jung B, Srivastava S. Comparison of Rifamycins for efficacy against Mycobacterium avium complex and resistance emergence in the hollow fiber model system. Front Pharmacol. 2021;12:645264.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2582_CR38","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1128\/JCM.01612-13","volume":"51","author":"BA Brown-Elliott","year":"2013","unstructured":"Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, Turenne CY, Wallace RJ. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389\u201394.","journal-title":"J Clin Microbiol"},{"key":"2582_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.027","volume":"55","author":"T Sch\u00f6n","year":"2017","unstructured":"Sch\u00f6n T, Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Int J Infect Dis. 2017;55:122\u20134.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"2582_CR40","doi-asserted-by":"publisher","first-page":"e00834","DOI":"10.1128\/JCM.00834-19","volume":"57","author":"BA Brown-Elliott","year":"2019","unstructured":"Brown-Elliott BA, Woods GL. Antimycobacterial susceptibility testing of nontuberculous Mycobacteria. J Clin Microbiol. 2019;57(10):e00834-19.","journal-title":"J Clin Microbiol."},{"issue":"4","key":"2582_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jiac.2017.10.022","volume":"24","author":"EH Cho","year":"2018","unstructured":"Cho EH, Huh HJ, Song DJ, Moon SM, Lee SH, Shin SY, Kim CK, Ki CS, Koh WJ, Lee NY. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. J Infect Chemother. 2018;24(4):315\u20138.","journal-title":"J Infect Chemother"},{"issue":"1","key":"2582_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40249-021-00844-1","volume":"10","author":"CF Liu","year":"2021","unstructured":"Liu CF, Song YM, He WC, Liu DX, He P, Bao JJ, Wang XY, Li YM, Zhao YL. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021;10(1):59.","journal-title":"Infect Dis Poverty"},{"issue":"7","key":"2582_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235797","volume":"15","author":"H Shuto","year":"2020","unstructured":"Shuto H, Komiya K, Goto A, Kan T, Honjo K, Uchida S, Takikawa S, Yoshimatsu T, Yamasue M, Hiramatsu K, et al. Efficacy and safety of fluoroquinolone-containing regimens in treating pulmonary Mycobacterium avium complex disease: a propensity score analysis. PLoS ONE. 2020;15(7): e235797.","journal-title":"PLoS ONE"},{"issue":"2","key":"2582_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jac\/dkw484","volume":"72","author":"JR Yuste","year":"2017","unstructured":"Yuste JR, Bert\u00f3 J, Del PJ, Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J Antimicrob Chemother. 2017;72(2):625\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2582_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/jac\/dkz511","volume":"75","author":"MM Ruth","year":"2020","unstructured":"Ruth MM, Koeken V, Pennings LJ, Svensson EM, Wertheim H, Hoefsloot W, van Ingen J. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother. 2020;75(3):609\u201317.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2582_CR46","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","volume":"152","author":"SL Martiniano","year":"2017","unstructured":"Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of Clofazimine for primary and refractory Nontuberculous Mycobacterial infection. Chest. 2017;152(4):800\u20139.","journal-title":"Chest"},{"key":"2582_CR47","doi-asserted-by":"publisher","first-page":"626216","DOI":"10.3389\/fmicb.2020.626216","volume":"11","author":"JM Lee","year":"2020","unstructured":"Lee JM, Park J, Choi S, Jhun BW, Kim SY, Jo KW, Hong JJ, Kim LH, Shin SJ. A Clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the Mycobacterium avium complex. Front Microbiol. 2020;11:626216.","journal-title":"Front Microbiol"},{"issue":"6","key":"2582_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2217\/fmb.10.50","volume":"5","author":"A Matteelli","year":"2010","unstructured":"Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010;5(6):849\u201358.","journal-title":"Future Microbiol"},{"issue":"3","key":"2582_CR49","doi-asserted-by":"publisher","first-page":"1601969","DOI":"10.1183\/13993003.01969-2016","volume":"49","author":"S Vesenbeckh","year":"2017","unstructured":"Vesenbeckh S, Sch\u00f6nfeld N, Krieger D, Bettermann G, Bauer TT, R\u00fcssmann H, Mauch H. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections. Eur Respir J. 2017;49(3):1601969.","journal-title":"Eur Respir J."},{"issue":"2","key":"2582_CR50","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JCM.02087-16","volume":"55","author":"DC Alexander","year":"2017","unstructured":"Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ. Emergence of mmpT5 variants during Bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol. 2017;55(2):574\u201384.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2582_CR51","doi-asserted-by":"publisher","first-page":"1900118","DOI":"10.1183\/13993003.00118-2019","volume":"54","author":"S Zweijpfenning","year":"2019","unstructured":"Zweijpfenning S, Schildkraut JA, Coolen J, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, et al. Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease. Eur Respir J. 2019;54(1):1900118.","journal-title":"Eur Respir J"},{"issue":"2","key":"2582_CR52","doi-asserted-by":"publisher","first-page":"e01798","DOI":"10.1128\/AAC.01798-16","volume":"61","author":"BA Brown-Elliott","year":"2017","unstructured":"Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ. In Vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother. 2017;61(2):e01798-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"2582_CR53","doi-asserted-by":"publisher","first-page":"e02627","DOI":"10.1128\/AAC.02627-16","volume":"61","author":"Y Pang","year":"2017","unstructured":"Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In Vitro activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017;61(5):e02627-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"2582_CR54","doi-asserted-by":"publisher","first-page":"e00665","DOI":"10.1128\/AAC.00665-19","volume":"63","author":"DH Kim","year":"2019","unstructured":"Kim DH, Jhun BW, Moon SM, Kim SY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Shin SJ, Daley CL, et al. In Vitro activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother. 2019;63(8):e00665-19.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"2582_CR55","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jinf.2015.12.007","volume":"72","author":"S Cowman","year":"2016","unstructured":"Cowman S, Burns K, Benson S, Wilson R, Loebinger MR. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect. 2016;72(3):324\u201331.","journal-title":"J Infect"},{"issue":"1","key":"2582_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2021.05.019","volume":"83","author":"Y Tan","year":"2021","unstructured":"Tan Y, Deng Y, Yan X, Liu F, Tan Y, Wang Q, Bao X, Pan J, Luo X, Yu Y, et al. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. J Infect. 2021;83(1):46\u201353.","journal-title":"J Infect"},{"key":"2582_CR57","doi-asserted-by":"crossref","unstructured":"Wang W, Yang J, Wu X, Wan B, Wang H, Yu F, Guo Y. Difference in drug susceptibility distribution and clinical characteristics between Mycobacterium avium and Mycobacterium intracellulare lung diseases in Shanghai, China. J Med Microbiol. 2021;70(5).","DOI":"10.1099\/jmm.0.001358"},{"issue":"5","key":"2582_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ijantimicag.2015.01.012","volume":"45","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Pang Y, Wang Y, Cohen C, Zhao Y, Liu C. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Agents. 2015;45(5):491\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2582_CR59","doi-asserted-by":"publisher","first-page":"e6263","DOI":"10.1371\/journal.pone.0006263","volume":"4","author":"V Saini","year":"2009","unstructured":"Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, Tyagi AK, Tyagi AK. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS ONE. 2009;4(7):e6263.","journal-title":"PLoS ONE"},{"issue":"2","key":"2582_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1128\/jcm.31.2.175-178.1993","volume":"31","author":"A Telenti","year":"1993","unstructured":"Telenti A, Marchesi F, Balz M, Bally F, B\u00f6ttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31(2):175\u20138.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"2582_CR61","doi-asserted-by":"publisher","first-page":"e203108","DOI":"10.1371\/journal.pone.0203108","volume":"13","author":"V Litvinov","year":"2018","unstructured":"Litvinov V, Makarova M, Galkina K, Khachaturiants E, Krasnova M, Guntupova L, Safonova S. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system. PLoS ONE. 2018;13(9):e203108.","journal-title":"PLoS ONE"},{"issue":"10","key":"2582_CR62","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/cid\/cix992","volume":"66","author":"T Nguyen","year":"2018","unstructured":"Nguyen T, Anthony RM, Ba\u00f1uls AL, Nguyen T, Vu DH, Alffenaar JC. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. CLIN INFECT DIS. 2018;66(10):1625\u201330.","journal-title":"CLIN INFECT DIS"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-022-02582-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-022-02582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T06:06:08Z","timestamp":1657260368000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-022-02582-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1186\/s12866-022-02582-2","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"5 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research for the current study has been approved by the Institutional Review Board (IRB) of Huashan Hospital, Fudan University (Number: 2021\u2013812). The collection of clinical MAC isolates from Huashan Hospital affiliated to Fudan University was permitted by the IRB. All experiments were performed in accordance with the latest CLSI guidelines for MIC measurement of MAC isolates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}